Supply of a medicinal product under the National Health Fund drug program for the treatment of patients with Pompe disease (ICD10: E74.0), containing alglucosidase alfa, for use in enzyme replacement therapy
Original notice title
Poland – Pharmaceutical products – Dostawa produktu leczniczego w ramach programu lekowego Narodowego Funduszu Zdrowia dotyczącego leczenia pacjentów z chorobą Pompego (ICD10: E74.0), zawierającego alglukozydazę alfa, do stosowania w enzymatycznej terapii zastępczej.
Opportunity Score
Why this score?
Opportunity
50 / 100
Complexity
20 / 100
Risk factors
Absence of estimated value or framework maximum increases financial uncertainty for bidders.
Strict exclusion criteria including criminal records, tax arrears, and EU sanctions compliance; failure to provide corr...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Overview
Moderate opportunityKey Facts
- Supplies contract
- 1 lot
- Duration 24 MONTH
- Supply of alglucosidase alfa (pharmaceutical product) for Pompe disease enzyme replacement therapy
- Delivery to the Hospital Pharmacy Department in Rawa Mazowiecka, Poland
Show full summary
This is an open tender by a Polish public hospital for the supply of alglucosidase alfa (Pompe disease drug) under an NFZ drug program. The contract is for 24 months, with electronic submission required. The award is based solely on price (100%). No estimated value is provided. The procurement documents are available on the buyer's platform but were not analyzed.
Risks
Absence of estimated value or framework maximum increases financial uncertainty for bidders.
Strict exclusion criteria including criminal records, tax arrears, and EU sanctions compliance; failure to provide corr...
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- Must hold a valid wholesale pharmaceutical permit (under Polish Pharmaceutical Law)
Eligibility
- Compliance with exclusion grounds under Article 108 of the Polish Public Procurement Law and EU sanctions related to Russia
Administrative
- Must submit a statement on the medicinal products (Annex 8 of SWZ)
Award Criteria
Lot 1
Buyer
Name
SAMODZIELNY PUBLICZNY ZAKŁAD OPIEKI ZDROWOTNEJ W RAWIE MAZOWIECKIEJ
Location
Rawa Mazowiecka, POL
Website
Buyer profile
Identifier
8351328753
Lots (1)
LOT-0001
Supply of a medicinal product under the National Health Fund drug program for the treatment of patients with Pompe disease (ICD10: E74.0), containing alglucosidase alfa, for use in enzyme replacement therapy
Successive delivery of alglucosidase alfa for Pompe disease enzyme replacement therapy, as detailed in Annex 2 (price form) of the procurement documents.
Location
Duration
Category
Selection criteria
Deadline
Award details
Show original TED data
Original lot title
Dostawa produktu leczniczego w ramach programu lekowego Narodowego Funduszu Zdrowia dotyczącego leczenia pacjentów z chorobą Pompego (ICD10: E74.0), zawierającego alglukozydazę alfa, do stosowania w enzymatycznej terapii zastępczej.
Original TED description
Przedmiotem zamówienia jest sukcesywna dostawa w ramach programu lekowego Narodowego Funduszu Zdrowia dotyczącego leczenia pacjentów z chorobą Pompego (ICD10: E74.0), zawierającego alglukozydazę alfa, do stosowania w enzymatycznej terapii zastępczej obejmujących pozycje wskazane i szczegółowo opisane w załączniku nr 2 formularz asortymentowocenowy do SWZ, do Działu Farmacji Szpitalnej – zgodnie z nazwą i ilością określoną w pakiecie
Procurement Details
- Publication date
- 18 Jun 2026
- Notice type
- Contract notice — standard
- Languages
- Polish
Reference metadata
- Notice subtype
- 16
- Notice version
- 1
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 424299-2026
Documents (1)
Similar tenders
Romania – Pharmaceutical products – Acord cadru privind achizitia publica de Medicamente, Materiale sanitare si Lapte praf
Poland – Pharmaceutical products – SZP.281.41.2026 Dostawa produktu leczniczego zawierającego substancję czynną – trastuzumab dla Instytutu „CZMP”
Sweden – Pharmaceutical products – Radioaktiva Läkemedel
Spain – Pharmaceutical products – Acuerdo marco para la adquisición de uniformes desechables para su utilización en los quirófanos con la cesión de máquinas dispensadoras que permitan su extracción personalizada HCD- 2a+2pr
France – Medical equipments – Fourniture de DMS Rythmologie
Poland – Pharmaceutical products – Cykliczne dostawy leków dla potrzeb Apteki Powiatowego Szpitala Specjalistycznego w Stalowej Woli w okresie 12 m-cy
Opportunity Score
Why this score?
Opportunity
50 / 100
Complexity
20 / 100
Risk factors
Absence of estimated value or framework maximum increases financial uncertainty for bidders.
Strict exclusion criteria including criminal records, tax arrears, and EU sanctions compliance; failure to provide corr...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications